Indication
Non-muscle invasive bladder cancer with carcinoma in situ
Non-muscle invasive bladder cancer with carcinoma in situ refers to high-grade urothelial malignancy confined to the inner mucosal lining of the urinary bladder without invasion into the underlying detrusor muscle layer. Read more about Non-muscle invasive bladder cancer with carcinoma in situ
7 drugs 5 manufacturers
Drugs that treat it
Common Non-muscle invasive bladder cancer with carcinoma in situ therapies.
KEYTRUDA (pembrolizumab)
ADSTILADRIN (nadofaragene firadenovec-vncg)
ANKTIVA (nogapendekin alfa inbakicept-pmln)
INLEXZO (gemcitabine HCl)
KEYTRUDA QLEX (pembrolizumab-berahyaluronidase alfa-pmph)
GEMCITABINE HCL-0.9% NACL (gemcitabine HCl in 0.9 % sodium chloride)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonNon-muscle invasive bladder cancer with carcinoma in situ refers to high-grade urothelial malignancy confined to the inner mucosal lining of the urinary bladder without invasion into the underlying detrusor muscle layer.
Unlike exophytic papillary lesions, carcinoma in situ appears pathologically as a flat, poorly differentiated lesion that carries a substantially elevated risk of disease recurrence and progression to muscle-invasive or metastatic disease.
It primarily affects older adults, presenting either alone (primary Tis) or concurrently with papillary tumors, and commonly manifests with microscopic or gross hematuria and irritative lower urinary tract symptoms.
- mayoclinic.org
Non-muscle invasive bladder cancer with carcinoma in situ refers to high-grade urothelial malignancy confined to the inner mucosal lining of the urinary bladder without invasion into the underlying detrusor muscle layer Unlike exophytic papillary lesions, carcinoma in situ appears pathologically as a flat, poorly differentiated lesion that carries a substantially elevated risk of disease recurrence and progression to muscle-invasive or metastatic disease It primarily affects older adults, presen...
- honcology.com
Non-muscle invasive bladder cancer with carcinoma in situ refers to high-grade urothelial malignancy confined to the inner mucosal lining of the urinary bladder without invasion into the underlying detrusor muscle layer
- nih.gov
Unlike exophytic papillary lesions, carcinoma in situ appears pathologically as a flat, poorly differentiated lesion that carries a substantially elevated risk of disease recurrence and progression to muscle-invasive or metastatic disease It primarily affects older adults, presenting either alone (primary Tis) or concurrently with papillary tumors, and commonly manifests with microscopic or gross hematuria and irritative lower urinary tract symptoms
Personalize your experience
Follow Non-muscle invasive bladder cancer with carcinoma in situ and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.